LUMEA is founded to develop standardized workflows for digital pathology, building a platform to link clinic, lab and pathologist in one system. They named it BxLink.

Partnered with Themis Pathology (Bucharest, Romania) to establish a Histochemistry R&D facility for multi-plexed and improved tissue embedding.

Established an integrated digital histology lab in a Provo warehouse, to implement and validate nascent technologies, including the BxChip.

Incorporated artificial intelligence into the digital imaging of gross tissue biopsy specimens, and commercialized the first AI-powered pathology workflow.

LUMEA digital prostate core mapping is developed and deployed as part of a major multi center FDA validation trial.

LUMEA launches R&D initiatives in Gastroenterology, Dermatology pre-analytics.

LUMEA technologies are adopted in multiple academic centers.

LUMEA technologies adopted in a national commercial laboratory.

LUMEA launches R&D initiative for low-cellularity / high value specimens and name it the CytoPod.

Independent clinical trials validate superior tissue handling and cost effectiveness of LUMEA lab workflow and tissue handling technologies.

LUMEA spins off its clinical lab into a separate diagnostic services company (PathNet Labs).

LUMEA is awarded 3 major patents relating to tissue handling, point-of-care imaging and the use of artificial intelligence in histology workflow.